0001493152-26-022697
SEC filingQ1 revenue declined 15.8% to $6.3M amid hospital staffing and cost pressures, partially offset by gross margin expansion to 60.3% from favorable product mix, with operating losses stable at -$6.0M due to lower headcount costs.
Stereotaxis reported Q1 2026 revenue of $6.3 million, down 15.8% from $7.5 million in the prior year quarter. This decline reflects ongoing challenges in the healthcare sector, where hospitals continue to grapple with staffing shortages and escalating cost pressures driven by supply chain constraints and inflation. These macroeconomic headwinds have constrained capital equipment purchases and procedure volumes, impacting Stereotaxis' revenue recognition tied to system placements and disposable usage.
Despite the revenue contraction, gross profit held relatively steady at $3.8 million, a 6.6% decrease from $4.1 million, resulting in gross margin expansion to 60.3%. As noted in management's discussion, this improvement stems primarily from changes in product mix, which favored higher-margin disposables and services over lower-margin systems. This mix shift demonstrates the resilience of Stereotaxis' core consumables business model, where recurring revenue from catheters and related products provides stability even as upfront system sales fluctuate with hospital budgets.
Net income showed a slight widening to -$5.9 million from -$5.8 million, with diluted EPS improving to -$0.06 from -$0.07 due to share count dynamics. Cash dynamics reflected heightened operational use, with net cash used in operating activities rising to -$3.4 million from -$1.8 million. This increase was driven by changes in working capital, underscoring the volatility inherent in Stereotaxis' business as inventory builds and receivables fluctuate with procedure timing.
Overall, the quarter illustrates Stereotaxis' ability to protect margins through mix management and cost discipline amid a challenging environment. Management continues to monitor macroeconomic conditions, adjusting inventory levels and vendor terms proactively. While near-term hospital pressures persist, the gross margin trajectory and expense controls position the company to capitalize on any recovery in procedure volumes, supported by its innovative robotic navigation technology.